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A B S T R A C T
Objectives: To project future antimicrobial resistance (AMR) in Escherichia coli and Klebsiella pneumoniae.
Methods: Mixed linear models were constructed from a sample of countries with AMR data in the
ResistanceMap database. Inverse probability weighting methods were used to account for countries
without AMR data.
Results: The estimated prevalence of AMR in 2015 was 64.5% (95% conﬁdence interval (CI) 42–87%) for
third-generation cephalosporin-resistant (3GCR) Escherichia coli, 5.8% (95% CI 1.8–9.7%) for carbapenem-
resistant (CR) E. coli, 66.9% (95% CI 47.1–86.8%) for 3GCR Klebsiella pneumoniae, and 23.4% (95% CI 7.4–
39.4%) for CR K. pneumoniae. The projected AMR prevalence in 2030 was 77% (95% CI 55–99.1%) for 3GCR
E. coli, 11.8% (95% CI 3.7–19.9%) for CR E. coli, 58.2% (95% CI 50.2–66.1%) for 3GCR K. pneumoniae, and 52.8%
(95% CI 16.3–89.3%) for CR K. pneumoniae.
Conclusions: The models suggest that third-generation cephalosporins and carbapenems could be
ineffective against a sizeable proportion of infections by E. coli and K. pneumoniae in most parts of the
world by 2030, supporting both the need to enhance stewardship efforts and to prioritize research and
development of new antibiotics for resistant Enterobacteriaceae.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Antimicrobial resistance (AMR) is now a global problem, and
resistance in Enterobacteriaceae, speciﬁcally Escherichia coli and
Klebsiella pneumoniae, is a critical threat to human health (World
Health Organization, 2014; WHO, 2018). Infections caused by
third-generation cephalosporin-resistant (3GCR) Enterobacteria-
ceae are associated with increased mortality, length of stay, and
costs compared with drug-sensitive strains (Stewardson et al.,
2016). Carbapenems are less reliable as last-resort antibiotics
because of increasing resistance (Gelband et al., 2015). AMR
already imposes a heavy economic burden on health systems
(Stewardson et al., 2016). Projecting future prevalence of AMR may
help prioritize research projects and interventions. The aims of this
study were to estimate global trends in AMR in E. coli and K.
pneumoniae and to project future AMR prevalence to 2030.
Methods
Data on population and gross national income per capita
(GNIPC) from the World Bank and on AMR from ResistanceMap, a
global repository of AMR data from quality-assured and accredited
hospitals and laboratory networks, were used (CDDEP, 2018).
Countries for which samples were obtained from a single hospital
were excluded from this study. Annual AMR data that had fewer
than 30 isolates were also excluded (Agresti and Caffo, 2000).
With few exceptions, low- and middle-income countries are
less likely to monitor AMR; therefore, high-income countries are
overrepresented in the ResistanceMap database. Not taking this
into account may lead to selection bias and an underestimation of
the prevalence of AMR because of the strong negative association
between GNIPC and the prevalence of AMR (Alvarez-Uria et al.,
2016). To overcome this problem, inverse probability of inclusion
(IPI) weighting, a method analogous to the use of inverse
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probability weights, was used to account for non-responders in
surveys (Dugoff et al., 2014). IPI weights were calculated based on
the inverse probability of being included in the study, using a
logistic regression model that included data from countries in the
world for which GNIPC data were available (countries with no
GNIPC data comprised 1.3% of the world population) (The World
Bank, 2018). In this logistic regression model, the availability of
national AMR data (thus being included in the study) was the
dependent variable, and orthogonal cubic spline transformations
of 2014 GNIPC and 2014 country populations were the indepen-
dent covariates (Dugoff et al., 2014). IPI weights gave more ‘weight’
to countries that were less likely to have AMR data in the
ResistanceMap database, based on their GNIPC and population.
This method helps generalize the results of the study to the world
population. IPI weights were multiplied by population weights,
which gives more weight to countries with larger populations, and
the results were used as probability or sample weights in the ﬁnal
mixed model with random intercept and slopes (Dugoff et al.,
2014). The mixed models were used to project AMR up to 2030.
Results
The study included 45 countries with AMR data for E. coli and 43
countries with AMR data for K. pneumoniae. In countries with E. coli
AMR data, the median number of AMR point estimates was 14
(interquartile range 1–15), and 31 were high-income countries. In
countries with K. pneumoniae AMR data, the median number of
AMR point estimates was 10 (interquartile range 2–14), and 28
were high-income countries. No country had AMR data beyond
2015.
Forecast estimates of global AMR are presented in Figure 1. The
estimated prevalence of AMR in 2015 was 64.5% (95% conﬁdence
interval (CI) 42–87%) for 3GCR E. coli, 5.8% (95% CI 1.8–9.7%) for
carbapenem-resistant (CR) E. coli, 66.9% (95% CI 47.1–86.8%) for
3GCR K. pneumoniae, and 23.4% (95% CI 7.4–39.4%) for CR K.
pneumoniae. The projected annual variation (slope) of AMR was
0.83% (95% CI 0.73–0.93%) for 3GCR E. coli, 0.4% (95% CI 0.12–0.68%)
for CR E. coli, 0.58% (95% CI 1.46% to 0.3%) for 3GCR K.
pneumoniae, and 1.96% (95% CI 0.59–3.33%) for CR K. pneumoniae.
Figure 1. Forecast estimates with 95% conﬁdence intervals of global resistance of Escherichia coli (A) and Klebsiella pneumoniae (B) to third-generation (3G) cephalosporins
and carbapenems based on population weighted mixed models with random slopes and intercepts.
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The projected AMR prevalence in 2030 was 77% (95% CI 55–99.1%)
for 3GCR E. coli, 11.8% (95% CI 3.7–19.9%) for CR E. coli, 58.2% (95% CI
50.2–66.1%) for 3GCR K. pneumoniae, and 52.8% (95% CI 16.3–89.3%)
for CR K. pneumoniae. Projections for individual countries with at
least four AMR point estimates using simple linear regression are
presented in the Supplementary material.
Discussion
The projections of AMR in this study signal a potentially serious
shortage of effective antimicrobials for common causes of infection
by 2030. Under current trends, over three-fourths of E. coli globally
will be 3GCR, and over half of K. pneumoniae invasive isolates will
be CR. The consequences of the high prevalence of AMR could be
devastating for health systems (World Health Organization, 2014;
de Kraker et al., 2011).
The models showed that the annual variation in the prevalence
of 3GCR K. pneumoniae was not signiﬁcantly different from zero,
with narrowing of the conﬁdence interval over time. This can be
explained by the fact that countries with initial low prevalence of
3GCR K. pneumoniae showed a rising trend over time, while the
trends were stable or mildly decreasing in countries with initial
high prevalence, such as India and South Africa (Supplementary
material, Figure S3). CR K. pneumoniae had the highest annual
increase of AMR, which could reach 53% by 2030, but the
conﬁdence intervals were wide, indicating uncertainty of the
projections. The projected increase in the prevalence of CR E. coli
was more modest. However, empirical treatment of infections will
need to cover 3GCR, leading to an increased use of carbapenems,
and this, in turn, may accelerate the pace of CR.
Enterobacteriaceae are part of the human gut microbiota, and
the spread of AMR is facilitated by conditions that are more
common in resource-poor settings, such as suboptimal sewage
systems and a lack of access to clean water (Holmes et al., 2016).
Previous studies have shown that resistance in Enterobacteriaceae
can emerge anywhere and spread around the globe (Nordmann
et al., 2011). Isolated interventions in high-income countries alone,
without intervention efforts in low- and middle-income countries,
may be ineffective in a globalized world (Nordmann et al., 2011).
This study has important limitations. The total population of all
countries included in the study was approximately a third of the
world population and was biased towards high-income countries.
While IPI models were used to attempt to correct for underrepre-
sentation of low- and middle-income countries, more surveillance
data are urgently needed to improve current and future estimates
of AMR. The projections for future levels of AMR were based on
linear models, which assumed no changes in the growth rate of
resistance. They also did not account for saturation or stabilization
of AMR levels, as was observed with 3GCR K. pneumoniae. In
addition, it was not possible to distinguish the case mix of
community- and hospital-acquired infections among the countries
included in the study, and the high prevalence of AMR in some
countries could be inﬂuenced by a higher proportion of hospital-
acquired infections (Dat et al., 2017; Thaden et al., 2017).
These results suggest that if current trends were to continue,
third-generation cephalosporins and carbapenems could become
ineffective against E. coli and K. pneumoniae in most parts of the
world in the not-too-distant future. Empirical antimicrobial
therapy for sepsis or for urinary tract or abdominal infections
might shift to non-beta-lactam antibiotics, which, in turn, may
lead to an increase in AMR in other antibiotic groups. These results
underscore the need to improve the judicious use of antimicrobials
and support recent World Health Organization recommendations
to prioritize the research, discovery, and development of new and
effective antibiotic treatments for beta-lactam-resistant Enter-
obacteriaceae (WHO, 2018).
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